全文获取类型
收费全文 | 262207篇 |
免费 | 25827篇 |
国内免费 | 12070篇 |
专业分类
耳鼻咽喉 | 3529篇 |
儿科学 | 5039篇 |
妇产科学 | 3419篇 |
基础医学 | 40058篇 |
口腔科学 | 6422篇 |
临床医学 | 21264篇 |
内科学 | 37484篇 |
皮肤病学 | 4880篇 |
神经病学 | 9357篇 |
特种医学 | 8698篇 |
外国民族医学 | 260篇 |
外科学 | 26339篇 |
综合类 | 45126篇 |
现状与发展 | 71篇 |
预防医学 | 7541篇 |
眼科学 | 3721篇 |
药学 | 18846篇 |
67篇 | |
中国医学 | 7758篇 |
肿瘤学 | 50225篇 |
出版年
2024年 | 187篇 |
2023年 | 3670篇 |
2022年 | 4988篇 |
2021年 | 9115篇 |
2020年 | 8896篇 |
2019年 | 8225篇 |
2018年 | 8292篇 |
2017年 | 9201篇 |
2016年 | 9986篇 |
2015年 | 11240篇 |
2014年 | 16387篇 |
2013年 | 16996篇 |
2012年 | 15380篇 |
2011年 | 17026篇 |
2010年 | 13963篇 |
2009年 | 13510篇 |
2008年 | 14084篇 |
2007年 | 14821篇 |
2006年 | 13575篇 |
2005年 | 12315篇 |
2004年 | 10497篇 |
2003年 | 9057篇 |
2002年 | 7477篇 |
2001年 | 6749篇 |
2000年 | 5575篇 |
1999年 | 4663篇 |
1998年 | 3885篇 |
1997年 | 3649篇 |
1996年 | 3221篇 |
1995年 | 3177篇 |
1994年 | 2865篇 |
1993年 | 2266篇 |
1992年 | 1955篇 |
1991年 | 1763篇 |
1990年 | 1409篇 |
1989年 | 1295篇 |
1988年 | 1208篇 |
1987年 | 975篇 |
1986年 | 880篇 |
1985年 | 1071篇 |
1984年 | 932篇 |
1983年 | 658篇 |
1982年 | 707篇 |
1981年 | 574篇 |
1980年 | 503篇 |
1979年 | 379篇 |
1978年 | 266篇 |
1977年 | 199篇 |
1976年 | 152篇 |
1975年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):301-326
ObjectiveThe use of mechanical circulatory support (MCS) in lung transplantation has been steadily increasing over the prior decade, with evolving strategies for incorporating support in the preoperative, intraoperative, and postoperative settings. There is significant practice variability in the use of these techniques, however, and relatively limited data to help establish institutional protocols. The objective of the AATS Clinical Practice Standards Committee (CPSC) expert panel was to review the existing literature and establish recommendations about the use of MCS before, during, and after lung transplantation.MethodsThe AATS CPSC assembled an expert panel of 16 lung transplantation physicians who developed a consensus document of recommendations. The panel was broken into subgroups focused on preoperative, intraoperative, and postoperative support, and each subgroup performed a focused literature review. These subgroups formulated recommendation statements for each subtopic, which were evaluated by the entire group. The statements were then developed via discussion among the panel and refined until consensus was achieved on each statement.ResultsThe expert panel achieved consensus on 36 recommendations for how and when to use MCS in lung transplantation. These recommendations included the use of veno-venous extracorporeal membrane oxygenation (ECMO) as a bridging strategy in the preoperative setting, a preference for central veno-arterial ECMO over traditional cardiopulmonary bypass during the transplantation procedure, and the benefit of supporting selected patients with MCS postoperatively.ConclusionsAchieving optimal results in lung transplantation requires the use of a wide range of strategies. MCS provides an important mechanism for helping these critically ill patients through the peritransplantation period. Despite the complex nature of the decision making process in the treatment of these patients, the expert panel was able to achieve consensus on 36 recommendations. These recommendations should provide guidance for professionals involved in the care of end-stage lung disease patients considered for transplantation. 相似文献
3.
4.
5.
6.
Bipul Gnyawali Antoinette Pusateri Ashley Nickerson Sajid Jalil Khalid Mumtaz 《World journal of gastroenterology : WJG》2022,28(29):3793-3802
Chronic Hepatitis B is a highly prevalent disease worldwide and is estimated to cause more than 800000 annual deaths from complications such as cirrhosis and hepatocellular carcinoma (HCC). Although universal hepatitis B vaccination programs may have reduced the incidence and prevalence of chronic hepatitis B and related HCC, the disease still imposes a significant healthcare burden in many endemic regions such as Africa and the Asia-Pacific region. This is especially concerning given the global underdiagnosis of hepatitis B and the limited availability of vaccination, screening, and treatment in low-resource regions. Demographics including male gender, older age, ethnicity, and geo graphic location as well as low socioeconomic status are more heavily impacted by chronic hepatitis B and related HCC. Methods to mitigate this impact include increasing screening in high-risk groups according to national guidelines, increasing awareness and health literacy in vulnerable populations, and developing more robust vaccination programs in under-served regions. 相似文献
7.
目的探讨肺癌患者化疗后的癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和鳞状上皮细胞癌抗原(SCC-Ag)表达变化。方法选取2017年5月至2020年2月间南京市六合区人民医院收治的100例肺癌患者,将这些患者作为肺癌组,另随机选取同期100例健康体检人员作为健康组。统计分析两组人员化疗前的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗成功患者化疗前后的血清NSE、CEA、SCC-Ag表达水平、肺癌组化疗失败患者化疗前后的血清NSE、CEA、SCC-Ag表达水平。结果肺癌组患者化疗前的血清NSE、CEA和SCC-Ag表达水平均高于健康组,差异均有统计学意义(均P <0.05)。肺癌组化疗成功患者化疗后的血清NSE、CEA和SCC-Ag表达水平均低于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。肺癌组化疗失败患者化疗后的血清NSE、CEA、SCC-Ag表达水平均高于化疗前,均高于健康组,差异均有统计学意义(P <0.05)。结论对肺癌患者的NSE、CEA、SCC-Ag表达水平进行检测能够将化疗效果有效反映出来,进而有效指导临床的下一步治疗工作,从而有效改善患者预后。 相似文献
8.
9.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
10.
Major depressive disorder is a serious and common neuropsychiatric disorder that affects more than 350 million people worldwide. Electroconvulsive therapy is the oldest and most effective treatment available for the treatment of severe major depressive disorder. Electroconvulsive therapy modifies structural network changes in patients with major depressive disorder and schizophrenia. And it can also affect neuroinflammatory responses and may have neuroprotective effects. Electroconvulsive therapy plays an irreplaceable role in the treatment of major depressive disorder. 相似文献